Novel therapies and vaccines against the human respiratory syncytial virus

Abstract : INTRODUCTION: Human respiratory syncytial virus (hRSV) is the leading cause of acute lower respiratory tract infections worldwide in infants, as well as an important pathogen affecting the elderly and immunocompromised individuals. Despite more than a half a century of research, no licensed vaccines are available and only palivizumab has been approved to use in humans, mostly recommended or limited to high risk infants. Therefore, novel therapeutic and preventive drugs need to be developed to fight this major human pathogen. AREAS COVERED: This review discusses current therapeutic approaches in preclinical and clinical stages, aimed at controlling or preventing hRSV infection. These methods include passive immunization, experimental drugs, vaccine candidates and maternal immunization. EXPERT OPINION: Based on the results of various immunization strategies and therapeutic approaches, it is likely that the most effective strategy against hRSV will be a prophylactic tool aimed at developing a strong antiviral T-cell response capable of both, promoting the generation of hRSV-specific high affinity antibodies and leading the protective immunity required to prevent the disease caused by this virus. Alternatively, if prophylactic strategies fail, antiviral drugs and novel passive immunity strategies could significantly contribute to reducing hospitalization rates in susceptible individuals.
Document type :
Journal articles
Complete list of metadatas

Cited literature [76 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-02149673
Contributor : Ana Paula Dutra Azevedo <>
Submitted on : Thursday, June 6, 2019 - 3:27:03 PM
Last modification on : Tuesday, August 13, 2019 - 2:30:12 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Collections

Citation

Claudia Rivera, Roberto Gomez, Rodrigo Díaz, Pablo Céspedes, Janyra Espinoza, et al.. Novel therapies and vaccines against the human respiratory syncytial virus. Expert Opinion on Investigational Drugs, Taylor & Francis, 2015, 24 (12), pp.1613-1630. ⟨10.1517/13543784.2015.1099626⟩. ⟨inserm-02149673⟩

Share

Metrics

Record views

49